VectivBio Holding AG (VECT) Stock
VECT is no longer traded. VectivBio Holding AG was acquired by Ironwood (IRWD) in July 2023.
Each VECT share was exchanged for $17.00 in cash. Prices on this page are historical; the last trade was July 6, 2023 at $16.85.
See Ironwood (IRWD) stock →VectivBio Holding AG stock price history
VECT final trading statistics
- Final close
- $16.85
- Final trading day
- Jul 6, 2023
- Market cap at delisting
- $1.06B
- Shares outstanding
- 62.81M
- Final 52-week range
- $4.25 – $16.98
- Avg. volume (final 3 mo.)
- 1,100,435
- All-time high (split-adj.)
- $24.23 · Apr 2021
- All-time low (split-adj.)
- $2.83 · Dec 2021
- Return since IPO
- -0.9%
- Beta
- 0.10
- Book value / share
- $3.40
- Price / book
- 4.95
VectivBio Holding AG annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $27.34M | -$93.7M | -$5.56 |
| FY2021 | $0.00 | -$87.0M | — |
| FY2020 | $0.00 | -$60.5M | — |
| FY2019 | $0.00 | -$23.5M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About VectivBio Holding AG
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
VectivBio Holding AG stock FAQ
What happened to VectivBio Holding AG stock?
VectivBio Holding AG was acquired by Ironwood (IRWD) in July 2023. Shareholders received $17.00 in cash for each share. VECT stock stopped trading on the Nasdaq, with a final close of $16.85 on July 6, 2023.
What did VectivBio Holding AG shareholders receive?
Each VECT share was converted into $17.00 in cash. The deal was valued at about $1.0 billion.
Is VECT stock still trading?
No. VECT was delisted from the Nasdaq in July 2023 and no longer trades on a U.S. exchange.
What was the last price of VECT stock?
VECT closed at $16.85 on its final trading day, July 6, 2023, for a market value of about $1.06B.
What were VectivBio Holding AG's revenue and earnings in its last full fiscal year?
VectivBio Holding AG reported revenue of $27.34M and net income of -$93.7M in fiscal 2022, its last full year as a public company.
When did VectivBio Holding AG go public?
VectivBio Holding AG stock began trading on April 8, 2021.